|
Author
|
Year
|
n
|
Cut-off
|
Standard-ised cut-off
|
Sens (%)
|
Spec (%)
|
PPV (%)
|
NPV (%)
|
Comment
|
|---|
|
Total
|
Adenoma (%)
|
AA (%)
|
|---|
|
Adenomas
| | | | | | | | | | | |
|
Kronborg
|
2000
|
814
|
203 (24.9)
|
–
|
10 mg/l
|
50
|
43.0
|
–
|
–
|
–
| |
|
Tibble
|
2001
|
233
|
29 (12.4)
|
–
|
10 mg/l
|
50
|
55.0
|
85.2*
|
45.7*
|
89.3*
| |
|
Kristinsson
|
2001
|
237
|
73 (30.8)
|
17 (7.2)
|
10 mg/l
|
50
|
56.2
|
47.4
|
40.6*
|
62.8*
| |
| | | | | |
15 mg/l
|
75
|
45.2
|
59.6
|
41.8*
|
63.0*
| |
| | | | | |
20 mg/l
|
100
|
31.5
|
71.1
|
41.1*
|
61.8*
| |
|
Damms
|
2008
|
140
|
29 (20.7)
|
–
|
50 μg/g
|
50
|
55.0
|
79.0
|
57.0
|
77.0
| |
|
Kalimutho
|
2011
|
192
|
69 (35.9)
|
34 (17.7)
|
45.8 ng/ml
| |
28.0
|
25.0*
|
21.0*
|
34.0*
| |
|
Widlak
|
2016
|
430
|
42 (9.8)
|
–
|
50 μg/g
|
50
|
43.0
|
56.0
|
10.0*
|
90.0*
| |
|
Rutka
|
2016
|
95
|
36 (37.9)
|
20 (21.1)
| | |
–
|
–
|
–
|
–
|
Faecal calprotectin significantly lower in low-risk adenoma compared to CRC
|
|
Advanced adenomas
| | | | | | | | | | | |
|
Hoff
|
2004
|
2321
|
–
|
195 (8.4)
|
50 μg/g
|
50
|
26.7*
|
76.1*
|
12.5*
|
89.0*
| |
|
Mowat
|
2015
|
755
|
–
|
41 (5.4)
|
50 μg/g
|
50
|
58.5
|
37.8
|
5.3
|
93.8
| |
| | | | | |
200 μg/g
|
200
|
19.5
|
73.7
|
4.3
|
93.8
| |
|
Lue
|
2020
|
404
|
41 (10.1)
|
39 (10)
|
50 μg/g
|
50
|
66.6
|
48.8
|
12.2
|
93.2
| |
|
Parente
|
2012
|
280
|
–
|
85 (30.4)
| | |
–
|
–
|
–
|
–
|
Significant differences between faecal calprotectin in both CRC and AA, and normal and AA (p < 0.001)
|
|
Turvill
|
2016
|
654
|
–
|
33 (5.0)
| | |
–
|
–
|
–
|
–
|
30/33 (90.9%) patients with AA had a high faecal calprotectin
|
- *Calculated value, AA advanced adenoma, PPV positive predictive value, NPV negative predictive value, standardised Cut-off: μg/g or mg/l multiplied by 5, –: no information available/ unable to calculate based on available information
